Completed PHASE3 INTERVENTIONAL 6-arm NCT01289119

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes

An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Determine the Efficacy and Safety of SYR-322 When Used in Subjects With Type 2 Diabetes

Sponsor: Takeda

Conditions Diabetes Mellitus, Type 2

Interventions Alogliptin Metformin Pioglitazone Placebo to alogliptin

Updated 6 times since 2017 Last updated: Feb 17, 2013 Started: Dec 31, 2010 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetes Mellitus, Type 2, this trial is completed. The trial is conducted by Takeda and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Fuzhou, China , Guangzhou, China , Haikou, China , Hangzhou, China , Harbin, China , Hong Kong, Hong Kong , Jinan, China and 11 more locations